Publications
Detailed Information
Simvastatin plus irinotecan, 5-fluorouracil, and leucovorin (FOLFIRI) as first-line chemotherapy in metastatic colorectal patients: a multicenter phase II study
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Lee, Jeeyun | - |
dc.contributor.author | Jung, Kyung Hae | - |
dc.contributor.author | Park, Young Suk | - |
dc.contributor.author | Ahn, Joong Bae | - |
dc.contributor.author | Shin, Sang Jun | - |
dc.contributor.author | Im, Seock-Ah | - |
dc.contributor.author | Oh, Do Youn | - |
dc.contributor.author | Shin, Dong Bok | - |
dc.contributor.author | Kim, Tae Won | - |
dc.contributor.author | Lee, Namsu | - |
dc.contributor.author | Byun, Jae Ho | - |
dc.contributor.author | Hong, Yong Sang | - |
dc.contributor.author | Park, Joon Oh | - |
dc.contributor.author | Park, Se Hoon | - |
dc.contributor.author | Lim, Ho Yeong | - |
dc.contributor.author | Kang, Won Ki | - |
dc.date.accessioned | 2010-01-29T04:48:13Z | - |
dc.date.available | 2010-01-29T04:48:13Z | - |
dc.date.issued | 2009-01-27 | - |
dc.identifier.citation | Cancer Chemother Pharmacol. 2009 Sep;64(4):657-63. Epub 2009 Jan 24. | en |
dc.identifier.issn | 1432-0843 (Electronic) | - |
dc.identifier.uri | http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=19169686 | - |
dc.identifier.uri | http://www.springerlink.com/content/nn7v53886n5808x4/fulltext.pdf | - |
dc.identifier.uri | https://hdl.handle.net/10371/46673 | - |
dc.description.abstract | BACKGROUND: Simvastatin has demonstrated anti-tumor activity in preclinical studies via tumor cell senescence, anti-angiogenesis, and apoptosis. This phase II trial evaluated the efficacy and toxicity profile of conventional FOLFIRI chemotherapy plus simvastatin in metastatic colorectal cancer patients. METHODS: Patients received irinotecan 180 mg/m(2) as a 90-min infusion followed by leucovorin 200 mg/m(2) in a 2-h infusion, and then 5-FU 400 mg/m(2) bolus injection followed by 2,400 mg/m(2) as a 46-h continuous infusion. Treatment cycles were repeated every 2 weeks until documented disease progression, unacceptable toxicity, or patient's refusal. Simvastatin 40 mg tablet was given once daily per oral everyday during the period of chemotherapy without a rest. RESULTS: From October 2005 to June 2006, 49 patients were enrolled. The overall response rate (ORR) was 46.9% (95% CI, 31.0-58.8) by intent-to-treat analysis and 45.8% (95% CI, 33.3-62.8) by per-protocol analysis. There were one complete response (CR) and 22 partial responses (PRs). Both CR and PRs were confirmed at least 4 weeks later. The disease-control rate was 83.7% (95% CI, 73.4-94.0). The median follow-up duration was 25.6 months (range, 20.9-28.8 months). The median survival of all patients was 21.8 months (95% CI, 14.4, 29.2). The median TTP was 9.9 months (95% CI, 6.4, 13.3). No patients experienced additional adverse effect that was definitely caused by simvastatin drug therapy in this trial. CONCLUSION: The combination of simvastatin plus FOLFIRI was a feasible regimen with promising antitumor activity. | en |
dc.language.iso | en | en |
dc.publisher | Springer Verlag | en |
dc.subject | Adult | en |
dc.subject | Aged | en |
dc.subject | Antineoplastic Combined Chemotherapy Protocols/adverse effects/*therapeutic use | en |
dc.subject | Female | en |
dc.subject | Camptothecin/administration & dosage/analogs & derivatives | en |
dc.subject | Fluorouracil/administration & dosage | en |
dc.subject | Humans | en |
dc.subject | Leucovorin/administration & dosage | en |
dc.subject | Male | en |
dc.subject | Middle Aged | en |
dc.subject | Neoplasm Metastasis | en |
dc.subject | Simvastatin/administration & dosage | en |
dc.title | Simvastatin plus irinotecan, 5-fluorouracil, and leucovorin (FOLFIRI) as first-line chemotherapy in metastatic colorectal patients: a multicenter phase II study | en |
dc.type | Article | en |
dc.contributor.AlternativeAuthor | 이지연 | - |
dc.contributor.AlternativeAuthor | 정경해 | - |
dc.contributor.AlternativeAuthor | 박영석 | - |
dc.contributor.AlternativeAuthor | 안중배 | - |
dc.contributor.AlternativeAuthor | 신상준 | - |
dc.contributor.AlternativeAuthor | 임석아 | - |
dc.contributor.AlternativeAuthor | 오도윤 | - |
dc.contributor.AlternativeAuthor | 신동복 | - |
dc.contributor.AlternativeAuthor | 김태원 | - |
dc.contributor.AlternativeAuthor | 이남수 | - |
dc.contributor.AlternativeAuthor | 변재호 | - |
dc.contributor.AlternativeAuthor | 홍용상 | - |
dc.contributor.AlternativeAuthor | 박준오 | - |
dc.contributor.AlternativeAuthor | 박세훈 | - |
dc.contributor.AlternativeAuthor | 임호영 | - |
dc.contributor.AlternativeAuthor | 강원기 | - |
dc.identifier.doi | 10.1007/s00280-008-0913-5 | - |
- Appears in Collections:
- Files in This Item:
- There are no files associated with this item.
Item View & Download Count
Items in S-Space are protected by copyright, with all rights reserved, unless otherwise indicated.